Japanese Journal of Clinical Oncology Advance Access published online on January 8, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyn145
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author (2009). Published by Oxford University Press. All rights reserved
A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Postoperative Hemithoracic Radiation for Malignant Pleural Mesothelioma
1 Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka
2 Department of Thoracic Surgery, Hyogo Cancer Center, Hyogo
3 Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima
4 Department of Radiation Oncology, Hyogo Cancer Center, Hyogo
5 Department of Radiation Oncology, Hyogo College of Medicine, Hyogo
6 Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
For reprints and all correspondence: Takashi Nakano, Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan. E-mail: t-nakano{at}hyo-med.ac.jp
Received July 14, 2008; accepted November 30, 2008
A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable malignant pleural mesothelioma. The study was initiated on May 2008 and 40 patients will be recruited over 3 years. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival.
Key Words: extrapleural pneumonectomy induction chemotherapy radiotherapy malignant pleural mesothelioma